The prevailing sentiment swirling around the biopharma sector is decidedly mixed. A survey conducted by RBC Capital Markets on investor views found that in the positive column investors are enthusiastic about the emergence of technology platforms such as gene therapy, cellular therapies and gene editing, but the industry's earnings report, while previously "viewed as a tailwind at the beginning of the year, it is now viewed as a headwind (perhaps after the lackluster 1Q and poor performance among large-caps)."